Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

Not yet recruiting

Conditions: Heart Failure
Preserved Ejection Fraction

First Posted Date: 2025-07-02

Last Posted Date: 2025-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3000

Registration Number: NCT07047508

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Not yet recruiting

Conditions: Heart Failure of Reduced Ejection Fraction (HFrEF)

First Posted Date: 2025-07-01

Last Posted Date: 2025-07-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7500

Registration Number: NCT07044700

Locations: 🇨🇳
Fuwai Hospital; National Center for Cardiovascular Diseases, Beijing, China

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Phase 2

Not yet recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BI 765423
Drug: Placebo

First Posted Date: 2025-06-25

Last Posted Date: 2025-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT07036523

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 38 locations

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: Vicadrostat
Drug: Jardiance®

First Posted Date: 2025-06-25

Last Posted Date: 2025-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT07035457

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

Phase 1

Not yet recruiting

Conditions: Healthy
Hepatic Impairment

Interventions: Drug: BI 1291583

First Posted Date: 2025-06-17

Last Posted Date: 2025-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT07023354

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Tranquil Clinical Research, Houston, Texas, United States
🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Phase 1

Not yet recruiting

Conditions: Borderline Personality Disorder
Attention Deficit Hyperactivity Disorder

Interventions: Drug: BI 3031185
Drug: Placebo

First Posted Date: 2025-06-03

Last Posted Date: 2025-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT07001475

Locations: 🇩🇪
Rheinhessen-Fachklinik Alzey, Alzey, Germany
🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany

and more 6 locations

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: BI 3810477
Drug: Placebo

First Posted Date: 2025-05-22

Last Posted Date: 2025-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT06984926

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Phase 2

Recruiting

Conditions: Macular Edema

Interventions: Drug: BI 1815368
Drug: Placebo

First Posted Date: 2025-05-08

Last Posted Date: 2025-06-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 300

Registration Number: NCT06962839

Locations: 🇺🇸
Retina Consultants Of Texas, The Woodlands, Texas, United States
🇺🇸
Retinal Consultants Medical Group, Inc, Modesto, California, United States
🇺🇸
Retina Consultants of San Diego, Poway, California, United States

and more 7 locations

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

Phase 1

Recruiting

Conditions: Cystic Fibrosis

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 285

Registration Number: NCT06962852

Locations: 🇫🇷
HOP Gui de Chauliac, Montpellier, France
🇫🇷
HOP Necker, Paris, France
🇮🇹
Istituto G. Gaslini, Genova, Italy

and more 7 locations

A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Empagliflozin

First Posted Date: 2025-05-08

Last Posted Date: 2025-07-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT06962826

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy